These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 32274544

  • 21. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM.
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [Abstract] [Full Text] [Related]

  • 22. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
    Hauke R.
    Drugs Today (Barc); 2018 Oct; 54(10):585-590. PubMed ID: 30398479
    [Abstract] [Full Text] [Related]

  • 23. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators.
    N Engl J Med; 2019 Jul 04; 381(1):13-24. PubMed ID: 31150574
    [Abstract] [Full Text] [Related]

  • 24. Treatment of Castration-naive Metastatic Prostate Cancer.
    Hamilou Z, Baciarello G, Fizazi K.
    Eur Urol Focus; 2017 Dec 04; 3(6):518-521. PubMed ID: 29500136
    [Abstract] [Full Text] [Related]

  • 25. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015 Dec 04; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 26. Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm.
    Paolieri F, Sammarco E, Ferrari M, Salfi A, Bonato A, Serafin D, Coccia N, Manfredi F, Zatteri L, Dima G, Carli C, Di Vita R, Oliveri M, Doni L, Galli L, Sisani M, Catalano M, Roviello G, Bloise F.
    Clin Genitourin Cancer; 2024 Aug 04; 22(4):102096. PubMed ID: 38759335
    [Abstract] [Full Text] [Related]

  • 27. Recent trends in the management of advanced prostate cancer.
    Ritch C, Cookson M.
    F1000Res; 2018 Aug 04; 7():. PubMed ID: 30345007
    [Abstract] [Full Text] [Related]

  • 28. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.
    Lancet Oncol; 2018 Feb 04; 19(2):194-206. PubMed ID: 29326030
    [Abstract] [Full Text] [Related]

  • 29. ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer.
    Küronya Z, Sükösd F, Varga L, Bíró K, Gyergyay F, Géczi L, Nagyiványi K, Jorgo K, Szarvas T, Kovács Á, Laczó I, Varga Z, Pósfai B, Pepó J, Maráz A.
    Urol Oncol; 2019 Apr 04; 37(4):289.e1-289.e9. PubMed ID: 30679082
    [Abstract] [Full Text] [Related]

  • 30. STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naïve prostate cancer: changing the LATITUDE.
    Klaassen Z, Murphy DG.
    BJU Int; 2018 Jan 04; 121(1):9-11. PubMed ID: 28990349
    [No Abstract] [Full Text] [Related]

  • 31. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov 04; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 32. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 04; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 33. Early use of chemotherapy in metastatic prostate cancer.
    Markowski MC, Carducci MA.
    Cancer Treat Rev; 2017 Apr 04; 55():218-224. PubMed ID: 27720577
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN, Tan PS, Simko S, Barreto CMN, Gutierres BS, Giglio AD, Lopes GL.
    Einstein (Sao Paulo); 2019 Mar 07; 17(2):eGS4414. PubMed ID: 30843996
    [Abstract] [Full Text] [Related]

  • 35. Apalutamide: A new agent in the management of prostate cancer.
    May MB, Glode AE.
    J Oncol Pharm Pract; 2019 Dec 07; 25(8):1968-1978. PubMed ID: 31359832
    [Abstract] [Full Text] [Related]

  • 36. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F.
    Lancet Oncol; 2018 Jul 07; 19(7):975-986. PubMed ID: 29880291
    [Abstract] [Full Text] [Related]

  • 37. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C, Massard C.
    Bull Cancer; 2015 Jun 07; 102(6):501-8. PubMed ID: 26022286
    [Abstract] [Full Text] [Related]

  • 38. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C, Jimeno A, Kessler ER.
    Drugs Today (Barc); 2019 Jan 07; 55(1):5-15. PubMed ID: 30740608
    [Abstract] [Full Text] [Related]

  • 39. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
    Dror CM, Chi KN.
    Future Oncol; 2020 Dec 07; 16(35):2905-2916. PubMed ID: 32885994
    [Abstract] [Full Text] [Related]

  • 40. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.
    Ponholzer A, Loidl W, Bektic J, Dorfinger K, Hruby S, Jeschke K, Kramer G, Krause S, Ludvik G, Remzi M, Roider M, Stoiber F.
    Wien Klin Wochenschr; 2016 Feb 07; 128(3-4):156-63. PubMed ID: 26831188
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.